NCT00276874View on ClinicalTrials.gov

Aripiprazole to Reduce Cocaine Relapse

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions
Cocaine-Related Disorders
Interventions
DRUG

Aripiprazole

Aripiprazole; 0-30 mg; oral; daily

DRUG

Placebos

Placebo; 0 mg; oral; daily

Trial Locations (1)

40506

University of Kentucky, Lexington

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Craig Rush

OTHER

NCT00276874 - Aripiprazole to Reduce Cocaine Relapse | Biotech Hunter | Biotech Hunter